Detalhe da pesquisa
1.
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.
Breast
; 54: 256-263, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33188992
2.
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]. / Attentes des patientes suivies pour un cancer de l'ovaire concernant les traitements d'entretien : résultats de la cohorte française GINECO de l'enquête européenne NOGGO/ENGOT-ov22 (Expression IV).
Bull Cancer
; 105(5): 465-474, 2018 May.
Artigo
em Francês
| MEDLINE | ID: mdl-29544693